The popularity of Sildenafil initially fueled a boom for major pharmaceutical companies, but recent shifts present a complicated scenario for investors. Lower-cost versions are eroding revenue, and persistent patent https://lucawlp032594.isblog.net/the-blue-pill-and-big-pharma-a-risky-bet-58494837